$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022003808 Filed on February 24, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$133.0K	$359.0K	$120.0K
YoY Change	10.83%	-1.91%	33.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.835M	$11.84M	$3.420M
YoY Change	12.13%	44.07%	125.0%
% of Gross Profit
Research & Development	$5.824M	$17.40M	$3.200M
YoY Change	82.0%	54.87%	11.89%
% of Gross Profit
Depreciation & Amortization	$113.0K	$451.0K	$120.0K
YoY Change	-5.83%	-3.22%	-66.67%
% of Gross Profit
Operating Expenses	$9.659M	$29.21M	$6.620M
YoY Change	45.91%	50.19%	51.14%
Operating Profit		-$28.86M
YoY Change		51.18%
Interest Expense	$84.00K	$0.00	-$70.00K
YoY Change	-220.0%	-100.0%	-240.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$564.0K	-$30.00K
YoY Change	-100.0%	-355.2%
Pretax Income	-$9.442M	-$28.29M	-$6.600M
YoY Change	43.06%	46.51%	55.66%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$9.442M	-$28.29M	-$6.600M
YoY Change	43.06%	46.53%	55.66%
Net Earnings / Revenue	-7099.25%	-7880.5%	-5500.0%
Basic Earnings Per Share		-$0.73
Diluted Earnings Per Share	-$232.5K	-$0.73	-$185.0K
COMMON SHARES
Basic Shares Outstanding	39.55M shares	39.03M shares	35.32M shares
Diluted Shares Outstanding		39.03M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$107.5M	$140.8M	$131.0M
YoY Change	-17.92%	7.5%	1184.31%
Cash & Equivalents	$11.94M	$11.94M	$131.0M
Short-Term Investments	$95.58M	$128.9M
Other Short-Term Assets	$4.771M	$4.771M	$2.100M
YoY Change	127.19%	127.19%	110.0%
Inventory
Prepaid Expenses	$4.771M		$2.055M
Receivables	$535.0K	$535.0K	$320.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$146.1M	$146.1M	$133.4M
YoY Change	9.58%	9.54%	1074.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$382.0K	$3.178M	$624.0K
YoY Change	-38.78%	217.8%	-28.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$239.0K	$239.0K	$404.0K
YoY Change	-40.84%	-40.25%	156.38%
Total Long-Term Assets	$3.417M	$3.417M	$1.371M
YoY Change	149.23%	162.85%	-20.88%
TOTAL ASSETS
Total Short-Term Assets	$146.1M	$146.1M	$133.4M
Total Long-Term Assets	$3.417M	$3.417M	$1.371M
Total Assets	$149.5M	$149.5M	$134.7M
YoY Change	11.0%	11.02%	929.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.439M	$1.439M	$1.366M
YoY Change	5.34%	2.79%	108.14%
Accrued Expenses	$4.527M	$4.523M	$3.851M
YoY Change	17.55%	7.69%	18.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.559M	$6.559M	$6.119M
YoY Change	7.19%	7.52%	27.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$2.568M	$156.0K
YoY Change	-100.0%	413.6%	21.53%
Total Long-Term Liabilities	$0.00	$2.568M	$156.0K
YoY Change	-100.0%	413.6%	21.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.559M	$6.559M	$6.119M
Total Long-Term Liabilities	$0.00	$2.568M	$156.0K
Total Liabilities	$9.127M	$9.127M	$6.569M
YoY Change	38.94%	38.29%	13.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$259.8M		-$231.5M
YoY Change	12.23%		10.82%
Common Stock	$4.000K		$4.000K
YoY Change	0.0%		-51.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$140.4M	$140.4M	$128.2M
YoY Change
Total Liabilities & Shareholders Equity	$149.5M	$149.5M	$134.7M
YoY Change	11.0%	11.02%	929.51%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$9.442M	-$28.29M	-$6.600M
YoY Change	43.06%	46.53%	55.66%
Depreciation, Depletion And Amortization	$113.0K	$451.0K	$120.0K
YoY Change	-5.83%	-3.22%	-66.67%
Cash From Operating Activities	-$7.390M	-$23.04M	-$5.120M
YoY Change	44.34%	41.22%	56.1%
INVESTING ACTIVITIES
Capital Expenditures	-$107.0K	$205.0K	-$60.00K
YoY Change	78.33%	-2.84%
Acquisitions
YoY Change
Other Investing Activities	-$8.687M	-$131.2M
YoY Change
Cash From Investing Activities	-$8.794M	-$131.4M	-$60.00K
YoY Change	14556.67%	62197.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$34.19M
YoY Change		-69.56%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.96M	$35.45M	99.76M
YoY Change	-85.0%	-74.18%	2146.85%
NET CHANGE
Cash From Operating Activities	-7.390M	-$23.04M	-5.120M
Cash From Investing Activities	-8.794M	-$131.4M	-60.00K
Cash From Financing Activities	14.96M	$35.45M	99.76M
Net Change In Cash	-1.222M	-$119.0M	94.58M
YoY Change	-101.29%	-198.55%	8053.45%
FREE CASH FLOW
Cash From Operating Activities	-$7.390M	-$23.04M	-$5.120M
Capital Expenditures	-$107.0K	$205.0K	-$60.00K
Free Cash Flow	-$7.283M	-$23.25M	-$5.060M
YoY Change	43.93%	40.66%	54.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35558
CY2021	dei	Entity Registrant Name EntityRegistrantName	CARDIFF ONCOLOGY, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2004382
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	11055 Flintkote Avenue
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	952-7570
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	258944643	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43306061	shares
CY2021	dei	Auditor Firm AuditorFirmId	243
CY2021	dei	Auditor Name AuditorName	BDO USA, LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11943000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130981000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	128878000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	535000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	320000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4771000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2055000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	146127000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	133356000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	382000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2796000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	343000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	239000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	404000	USD
CY2021Q4	us-gaap	Assets Assets	149544000	USD
CY2020Q4	us-gaap	Assets Assets	134727000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1439000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1366000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4527000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3851000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	551000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	860000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6559000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6119000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	285000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2568000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	156000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	9127000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	6569000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41964000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41964000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36781000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36781000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400503000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	361819000	USD
CY2021Q4	crdf	Servicereceivable Servicereceivable	139000	USD
CY2020Q4	crdf	Servicereceivable Servicereceivable	2171000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-142000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-259810000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-231495000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128158000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149544000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134727000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	359000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	366000	USD
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17376000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11235000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11838000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8217000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	29214000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	19452000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-28855000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-19086000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	264000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	90000	USD
CY2021	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Interest Expense InterestExpense	2000	USD
CY2021	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	15000	USD
CY2020	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-28000	USD
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	285000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-281000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	564000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-221000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28291000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19307000	USD
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	USD
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28315000	USD
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22598000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39030000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39030000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20875000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20875000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28291000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19307000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-142000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28433000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19307000	USD
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24000	USD
CY2021	crdf	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-28457000	USD
CY2020	crdf	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-22598000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7312000	USD
CY2020	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	112300000	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-8000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1765000	USD
CY2020	crdf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	24871000	USD
CY2020	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000	USD
CY2020	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	1101000	USD
CY2020	crdf	Adjustments To Additional Paid In Capital Common Stock Par Value Adjustment AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment	0	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	148000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19307000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128158000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3234000	USD
CY2021	crdf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1263000	USD
CY2021	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	34187000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-142000	USD
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000	USD
CY2021	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	2032000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28291000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	USD
CY2020	crdf	Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	7500000	USD
CY2020	crdf	Warrants Fair Value WarrantsFairValue	400000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	800000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28291000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19307000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2021	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	USD
CY2020	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	34000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	451000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	466000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3234000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1765000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1607000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	285000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-281000	USD
CY2021	crdf	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	2032000	USD
CY2020	crdf	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	1100000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-166000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	246000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	215000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	117000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2099000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1100000	USD
CY2021	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-607000	USD
CY2020	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-320000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	719000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1276000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-811000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-857000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-156000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	70000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23040000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16315000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	205000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	211000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	28391000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	174385000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	14751000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131448000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-211000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	34187000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	112300000	USD
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-8000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1263000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	24872000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	148000	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	305000	USD
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	305000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35450000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137312000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-119038000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	120786000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130981000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10195000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11943000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130981000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	24000	USD
CY2020	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	24000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	140800000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimate involves accrued clinical trial expenses.</span></div>
CY2021Q4	crdf	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	1600000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17400000	USD
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	6000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars.
CY2021	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	95643000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10947627	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9807474	shares
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	65000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	95584000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	33377000	USD
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	1000	USD
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	84000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	33294000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	129020000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	149000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	128878000	USD
CY2021	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	USD
CY2021	us-gaap	Depreciation Depreciation	500000	USD
CY2020	us-gaap	Depreciation Depreciation	500000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3823000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3628000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3441000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3004000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	382000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1435000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1523000	USD
CY2021Q4	crdf	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	414000	USD
CY2020Q4	crdf	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	390000	USD
CY2021Q4	crdf	Accrued Clinical Trial AccruedClinicalTrial	1639000	USD
CY2020Q4	crdf	Accrued Clinical Trial AccruedClinicalTrial	1557000	USD
CY2021Q4	crdf	Accruedresearchagreements Accruedresearchagreements	726000	USD
CY2020Q4	crdf	Accruedresearchagreements Accruedresearchagreements	67000	USD
CY2021Q4	crdf	Accrueddirectorfees Accrueddirectorfees	141000	USD
CY2020Q4	crdf	Accrueddirectorfees Accrueddirectorfees	93000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	63000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	38000	USD
CY2021Q4	crdf	Patentlicenseandotherfeespayable Patentlicenseandotherfeespayable	43000	USD
CY2020Q4	crdf	Patentlicenseandotherfeespayable Patentlicenseandotherfeespayable	117000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	66000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	66000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4527000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3851000	USD
CY2021	crdf	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
CY2021	crdf	Lessee Operating Lease Area Of Lease Occupied By Company LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany	9500	sqft
CY2021	crdf	Lessee Operating Lease Area Of Lease LesseeOperatingLeaseAreaOfLease	26100	sqft
CY2021	crdf	Lessor Area Of Sublease LessorAreaOfSublease	16600	sqft
CY2021	crdf	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	80000	USD
CY2021	crdf	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
CY2021	crdf	Lessor Area Of Sublease LessorAreaOfSublease	16600	sqft
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	745000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	441000	USD
CY2021	us-gaap	Sublease Income SubleaseIncome	403000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	291000	USD
CY2021	us-gaap	Lease Cost LeaseCost	342000	USD
CY2020	us-gaap	Lease Cost LeaseCost	150000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2796000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	343000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	551000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	860000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2568000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3119000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	869000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	949000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	944000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3061000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	551000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	737000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	754000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	775000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	796000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	136000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3749000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	630000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3119000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10589482	shares
CY2019Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	4.08
CY2019	crdf	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P3Y8M12D
CY2020	crdf	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	5831451	shares
CY2020	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	1.70
CY2020	crdf	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	11159941	shares
CY2020	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	2.31
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5260992	shares
CY2020Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.19
CY2020	crdf	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P4Y1M6D
CY2021	crdf	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	770833	shares
CY2021	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	1.64
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4490159	shares
CY2021Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.80
CY2021	crdf	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P3Y
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2020Q2	crdf	Class Of Warrant Or Right Months Until Exercisable ClassOfWarrantOrRightMonthsUntilExercisable	P6M
CY2020Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1546700	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2213115	shares
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	863852	shares
CY2020Q2	crdf	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	2700000	USD
CY2020Q2	crdf	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	184426	shares
CY2020Q2	crdf	Class Of Warrant Or Right Months Until Exercisable ClassOfWarrantOrRightMonthsUntilExercisable	P6M
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.05
CY2020Q2	crdf	Class Of Warrant Or Right Expiration Term ClassOfWarrantOrRightExpirationTerm	P5Y6M
CY2020Q2	crdf	Warrants Fair Value WarrantsFairValue	370666	USD
CY2020Q1	crdf	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	1000000	USD
CY2020Q2	crdf	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	1100000	USD
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	447761	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.34
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	146854	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.43
CY2020Q2	crdf	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	810000	USD
CY2020Q2	crdf	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	2500000	USD
CY2020Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	6500000	shares
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.50
CY2020Q4	crdf	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	100900000	USD
CY2020Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	94000000	USD
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2000000	shares
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2021Q2	crdf	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	20000000	USD
CY2021Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2400000	shares
CY2021Q4	crdf	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	15000000	USD
CY2021Q4	crdf	Securities Purchase Agreement Number Of Days Counterparty Cannot Sell Or Transfer Shares SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares	P180D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3150000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	600000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3234000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1765000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1200000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1500000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	300000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6082000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5551000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4043000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-531000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-92000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4135000	USD
CY2021Q4	crdf	Valuation Allowance ValuationAllowance	6081000	USD
CY2020Q4	crdf	Valuation Allowance ValuationAllowance	4134000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5941000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4054000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-233000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-122000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2021	crdf	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	62000	USD
CY2021	crdf	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	0
CY2020	crdf	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	261000	USD
CY2020	crdf	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	325000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	81000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.01
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	366000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.01
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6081000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.02
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	72000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4134000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	6000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	611000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	80000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47902000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42331000	USD
CY2021Q4	crdf	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	4035000	USD
CY2020Q4	crdf	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	3904000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	962000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	684000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1750000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1116000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54649000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	48035000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	611000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	74000	USD
CY2021Q4	crdf	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	54038000	USD
CY2020Q4	crdf	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	47955000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54038000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47955000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD

Files In Submission

Name	View Source	Status
0001628280-22-003808-index-headers.html	Edgar Link	pending
0001628280-22-003808-index.html	Edgar Link	pending
0001628280-22-003808.txt	Edgar Link	pending
0001628280-22-003808-xbrl.zip	Edgar Link	pending
a231exq42021.htm	Edgar Link	pending
a311exq42021.htm	Edgar Link	pending
a312exq42021.htm	Edgar Link	pending
a321exq42021.htm	Edgar Link	pending
a322exq42021.htm	Edgar Link	pending
crdf-20211231.htm	Edgar Link	pending
crdf-20211231.xsd	Edgar Link	pending
crdf-20211231_cal.xml	Edgar Link	unprocessable
crdf-20211231_def.xml	Edgar Link	unprocessable
crdf-20211231_htm.xml	Edgar Link	completed
crdf-20211231_lab.xml	Edgar Link	unprocessable
crdf-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2021 Q4 Form 10-K Financial Statement

#000162828022003808 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2021 Q4 Form 10-K Financial Statement

#000162828022003808 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf